Performance of the T2Candida Panel for the Diagnosis of Intra-abdominal Candidiasis

Frederic Lamoth; Cornelius J Clancy; Frederic Tissot; Kevin Squires; Philippe Eggimann; Ursula Flückiger; Martin Siegemund; Christina Orasch; Stefan Zimmerli; Thierry Calandra; Oscar Marchetti; Minh H Nguyen; Pierre-Yves Bochud

doi:10.1093/ofid/ofaa075

Performance of the T2Candida Panel for the Diagnosis of Intra-abdominal Candidiasis

Open Forum Infect Dis. 2020 Feb 27;7(3):ofaa075. doi: 10.1093/ofid/ofaa075. eCollection 2020 Mar.

Authors

Affiliations

¹ Infectious Diseases Service, Department of Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
² Institute of Microbiology, Department of Laboratories, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
³ Division of Infectious Diseases, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
⁴ Service of Orthopedics and Traumatology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
⁵ Division of Infectious Diseases and Hospital Epidemiology, Department of Medicine, University Hospital of Basel, Basel, Switzerland.
⁶ Intensive Care Unit, University Hospital of Basel, Basel, Switzerland.
⁷ Hirslanden Klinik St. Anna, Luzern, Switzerland.
⁸ Department of Infectious Diseases, Bern University Hospital, Bern, Switzerland.
⁹ Hôpital de Morges, Ensemble Hospitalier de La Côte, Morges, Switzerland.

Abstract

Performance of T2Candida for detecting intra-abdominal candidiasis (IAC) was assessed in 48 high-risk patients. T2Candida sensitivity/specificity and positive/negative predictive values were 33%/93% and 71%/74%, respectively. IAC was present in 100% of cases with concordant positive T2Candida/1,3-beta-d-glucan and absent in 90% of concordant negative results. Combination T2Candida/1,3-beta-d-glucan may help guide treatment decisions.

Keywords: T2 magnetic resonance; beta-glucan; blood cultures; candidemia; invasive candidiasis.